University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Chemical & Biomolecular Engineering Theses,
Dissertations, & Student Research

Chemical and Biomolecular Engineering,
Department of

12-2012

Application of Response Surface Methodology and Central
Composite Design for 5P12-RANTES Expression in the Pichia

pastoris System
Frank M. Fabian
University of Nebraska-Lincoln, frankfabsan@gmail.com

Follow this and additional works at: https://digitalcommons.unl.edu/chemengtheses
Part of the Other Biomedical Engineering and Bioengineering Commons

Fabian, Frank M., "Application of Response Surface Methodology and Central Composite Design for
5P12-RANTES Expression in the Pichia pastoris System" (2012). Chemical & Biomolecular Engineering
Theses, Dissertations, & Student Research. 16.
https://digitalcommons.unl.edu/chemengtheses/16

This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department
of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Chemical &
Biomolecular Engineering Theses, Dissertations, & Student Research by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.

APPLICATION OF RESPONSE SURFACE METHODOLOGY AND CENTRAL
COMPOSITE DESIGN FOR 5P12-RANTES EXPRESSION IN THE Pichia pastoris
SYSTEM

By
Frank M. Fabian

A THESIS
Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Chemical Engineering

Under the Supervision of Professor William H. Velander

Lincoln, Nebraska
December, 2012

APPLICATION OF RESPONSE SURFACE METHODOLOGY AND CENTRAL
COMPOSITE DESIGN FOR 5P12-RANTES EXPRESSION IN THE Pichia pastoris
SYSTEM
Frank M. Fabian, M.S.
University of Nebraska, 2012
Adviser: William H. Velander
Pichia pastoris has demonstrated the ability to express high levels of recombinant
heterologous proteins. Protein expression is enhanced during fermentation at high cell
density. However, the level of expression is mainly regulated by fermentation operation
factors. This research is directed to investigate the effect of methanol growth rate,
temperature and pH in the expression of the total 5P12-Rantes concentration, expression
of active 5P12-Rantes and Specific yield using the response surface methodology and
central composite design.
The response surface methodology, RSM, has been used successfully used by
Zhang, W. and Ian, M. to optimize the cell density and fermentation process. The RSM is
equipped with statistical tools to determine the significance of a factor over a response.
The evaluation of factors using the RSM uses experimental design in order to distribute
the selected variables within the boundaries of the design.
The central composite design, CCD, allows allocation of Methanol growth rate,
temperature, and pH to evaluate their effect in the expression of 5P12-Rantes. The effect
of methanol growth rate is evaluated from a minimum value of 0.01 h-1 to a maximum of
0.4 h-1, 24.06 °C to 29.94 °C for temperature and 1.99 to 4.51 for pH.

The methanol growth rate has demonstrated to have no effect in any of the
responses. In contrast, Temperature and pH has a significant effect in all the responses.
However, the lack of fit of the proposed model doesn’t allow good estimations of
predicted responses. In order to minimize the lack of fit of the propose models, the
methanol growth rate has been excluded from all the three models. A new 2 factor second
order model is proposed to analyze the significance of temperature and pH. The lack of
fit decreased and the optimal operating conditions for temperature and pH was
determined at 27.14 °C and 3.16 which results in a maximum of 26.52 g/L of active
5P12-Rantes and 0.16 mg Rantes/g dry cell.
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CHAPTER I
LITERATURE REVIEW
ABSTRACT
The characterization of the HIV-1’s envelope proteins has provided an abundant
knowledge about the viral structure conformation. However, the discovery of the
infection mechanism has made possible the development of drugs to prevent HIV-1
infection. The sequence of HIV-1 infection is mainly characterized by a series of
conformational modifications in the viral envelope proteins. These modifications direct
the interaction of the virus with the target cell and thereafter the delivery the RNA viral
information.
Human cells express an incredible variety of proteins directed to protect them
against diseases. For example, Regulated-on-Activation-Normal-T-cells-Expressed-andSecreted, RANTES, has chemoattractant activity for monocytes and it is expressed in
response to viral infection. This protein is expressed by the immune cells called cytotoxic
phenotype CD8+ and the helper CD4+ T cell in response to the detection of a foreign
microorganism. Unfortunately, in the case of HIV-1, the expression of RANTES occurs
after the cells have been infected by the virus.
The development of effective therapies to protect against HIV-1 viral infection
has focused upon the design of drugs with the capability to interfere with the infection
mechanism. For example, 5P12-Rantes, a homologous of human RANTES, has proved
protection against HIV-1 infection by competitive interaction with the co-receptor CCR5.
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The chapter discusses the HIV-1 entry mechanism and describes the
conformational modifications of the viral envelope proteins. The functional activity of the
5P12-Rantes is described as part of viral entry inhibition.
INTRODUCTION
HIV-1 Entry Mechanism
The HIV-1entry mechanism depends on the sequential interaction of the virion
envelope glycoproteins 120 and 41 (gp120 and gp41) with cellular receptor cluster of
differentiation (CD4) and co-receptor chemokine type 5 or CCR5 (Rizzuto et al. 1998).
Initially, the virion binds to the host cell receptor (T cells) by non-covelant interaction
between the virion surface envelope glycoprotein, gp120, and the protein receptor, CD4.
Once CD4 binds the virion envelope glycoprotein gp120, the later undergoes a change in
its conformation that enables it to engage the co-receptor CCR5. This step then triggers
fusion of the virus with the cell membrane (Wilen et al. 2012). Finally, gp120 dissociates
from the membrane-anchored gp41. Then, gp41 refolds in a series of sequential steps that
leads to a closer contact of the viral envelop (Env) with the cell membrane (Liu, et al.
2008). The viral core is then delivered into the host cell. (Chen, et al. 2005)
The primary and tertiary structure and of both the virion envelope glycoprotein,
gp120, and the cell receptor, CD4, play an important role in the ultimate formation of the
envelope complex. (Wu,et al 1996) The virion envelope glycoprotein structure is showed
in Figure 1.1. The gp120 , synthesized in the endoplasmic reticulum, consists of 25 βstrands, 5α helices and 10 defined loop segments (Kwong et al. 1998). The gp120 is
found as trimers on the surface of the viral membrane.(Liu, et al 2008) and it is folded
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into two major domains: five highly conserved inner domains (C1-C5) and five hyper
variable loops (V1-V5). The conserved domains are important for gp120 folding and
binding of the co-receptor, CCR5 (Rizzuto et al. 1998), the variable domains are involved
in immune evasion and conformational modifications. (Wilenet al.2012)
The cellular receptor CD4 is an immunoglobin protein conformed of three
regions: an extracellular region, a hydrophobic trans membrane domain, and a highly
charged cytoplasmic domain containing 370, 26, and 38 amino acid residues respectively.
(Capon et al. 1991) The extracellular region of CD4 contains four recognized
immunoglobin (Ig)-like domains denoted D1,D2,D3 and D4. (Harrison et al. 1992). D1
and D2, showed in Figure 1.2, are defined as the membrane distal two-domain fragment;
meanwhile D3 and D4 are known as the membrane proximal two-domain fragment. In
particular the D1 domain contains a specific binding site for the glycoprotein, gp120 (Wu
et al. 1996)

Figure 1.1: A ribbon drawing of the HIV-1 glyco protein 120 (gp120)
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Figure 1.2: Ribbon diagram showing organization of the distal two domain fragment
D1and D2 of the CD4 cellular receptor
GP120 undergoes a change in its structural conformational after binding the
protein receptor CD4. This complex is mediated by chemokine receptor CCR5. (Kwong,
et al., 1998). The D1-D2 extracellular fragment of CD4 the receptor protein binds gp120
in a depressed region formed at the interface of the outer domain with the inner domain
and the bridging sheet of the gp120 (Figure 1.3). This region is surrounded by
carbohydrate moieties and is partially occluded by the flexible loops V1 and V2. (Wilen.
et al. 2012). The molecular interaction between CD4 and gp120 occurs by direct
interatomic contacts between 22 CD4 amino acids residues and 26 gp120 amino acid
residues which results in 219 van der Waals contacts and 12 hydrogen bonds. The most
important interactions, Phe43 and Arg59 of CD4 make multiple contacts on residues
Asp368, Glu370, and Trp427 of gp120. (Kwong, et al., 1998) These interactions induce
the conformational modification of the conserved inner domain of gp120 promoting the
independent moving of each domain (Chen, et al. 2005) This modification is enhanced
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by the flexibility of the D1-D2 domains of CD4 (Liu, et al 2008) The overall
modification induced by these interactions causes:a 30° rotation of the three strand
antiparallel sheet , the formation of four-stranded bridging sheet , and the displacement of
the four-turn α-helix away from the outer domain (Figure 1.4). (Chen, et al. 2005). As a
result, the V3 loop region is released from the lateral edge of the glycoprotein 120 and
oriented into the target cell (Liu, et al 2008).

Figure 1.3: Un-ligated SIV gp120 core structure
The complex formed during the interaction of gp120 and CD4 causes viral
proteins to bind the chemokine co-receptor type 5 (CCR5) (Wilen et al. 2012). CCR5 is a
trans membrane protein that contains 352 amino acids and has a molecular mass of 40.6
kDa (Figure 1.5). The CCR5 has 3 external closed loops (ECL1, ECL2, ECL3) and 4
internal closed loops (ICL1, ICL2, ICL3, ICL4). This chemokine receptor is expressed in
T-lymphocytes with memory/effector phenotype, monocytes, macrophage, and immature
dentritic cells. The amino acids aspartic acid and glutamic acid at the N-terminal of
CCR5 confer acidic properties to CCR5 (Oppermann et al. 2004). Additional negative
charges are conferred by sulfation of tyrosine residues at positions 3,10,14 and 15(Farzan
et al. 1999) and improves the capability of CCR5 to interact with the envelope
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glycoprotein, gp120. (Oppermann et al. 2004). Furthermore, tyrosine-sulfated residues in
the N-terminal of CCR5 bind the V3 loop and the bridging sheet. In order to bind the
sulfated tyrosine residue at the CCR5 receptor, the V3 loop is modified into a rigid βhairpin by additional conformational changes of the gp120 (Huang et al. 2007) caused by
formation of numerous hydrogen bonds in the V3 loop. (Wilen et al. 2012)

Figure 1.4: Conformational changes in the gp120 during binding of the protein receptor
CD4.
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Figure 1.5: Two dimensional topology of the Human CCR5 sequence.
The viral genomic load is delivered to the cell by a generalized “cast-and-fold”
fusion mechanism induced by a conformational change of the glycoprotein, gp41.
(Melikyan et al, 2008). The core of gp41 , showed in Figure 1.6, is composed of a trimer
of two interacting peptides. Structurally, the gp41 is formed by six helical bundles. The
internal N-terminal helical regions (HR-N) is formed of three parallel coiled-coiled
trimer, meanwhile the C-terminal helical regions (HR-C) are packed in an oblique,
antiparallel manner to form highly conserved, hydrophobic grooves in the surface of this
trimer. (Chan et al, 1997).The result is a highly stable six-helix bundle (6HB) (Wilen et
al, 2012). However, a delivery pore is initially catalyzed by pre-bundle and energetically
unstable structures. These occurs in the HR1 and HR2 regions and are critical for fusion.
(Melijyan et al. 2008) The early pre-bundle is characterized by the maximization of the
distance between HR-N and HR-C. Meanwhile, the late pre-bundle describe the
formation of the nascent fusion pore (Wilen et al. 2012). Finally, the 6HB dilates the
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delivery pore to a size that permits the transfer of the viral load (Figure 1.6). (Melikyan,
et al 2008)

Figure 1.6: HR-C and HR-N of the gp41
Inhibition of HIV entry
Inhibition of the HIV entry mechanism can occur at any of the three major steps
of the interaction between the viral envelope proteins and cell membrane protein
receptors. The inhibition of the attachment and binding of receptor CD4, binding of coreceptor CCR5, and membrane fusion are the principal focus for the development of
drugs that can limit the infectivity of the virus. (Wilen et al. 2012).The discovery of
mechanistically novel HIV-1 inhibitors has resulted in the development of new drugs like
Enfuvirtide (Meanwell et al. 2003) and Maraviroc (Lieberman-Blum et al. 2008) that
interfere with the function of gp41 and CCR5 interaction respectively. Although these
drugs are relative important to prevent the HIV entry, the study of the inhibition of the
three other stages of entry mechanism is also to understand the drug activity and design
(Wiley et al. 2012).
Several anionic polymers have been shown to inhibit the attachment and binding
of gp120 with CD4. These anionic organic compounds that include various naphthalene
disulfonates disrupt the interaction of the gp120–CD4 that suppresses the efficiency of
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HIV-1 infection (Rusconi et al. 1996). These polymers are directed to prevent the
electrostatic interaction between the positively charged viral envelope and the negatively
charged cell surface. However, these polymers have not in vivo efficacy when used as
vaginal microbicide (Wiley et al. 2012). In contrast, other drugs which target the CD4
binding site in gp120 have shown promising activity to prevent further interaction
between the viral envelope and the CD4 receptor. For example, BMS-378806 is a small
molecule that binds gp120 and inhibits the interaction of the envelope protein and the
cellular receptor (Lin et al. 2003). Another small molecule drug, BMS-488043 directly
inhibits the conformational changes of the CD4 and CCR5 binding sites in the gp120.
(Ho et al. 2006).
The discovery of resistance to HIV-1 infection in individuals with mutation in
CCR5 demonstrates that this co-receptor is essential element of virus – cell membrane
fusion. The mutant allele the CCR-5, Δccr-5, prevents membrane fusion (Libert et al,
1998). A 32-bp deletion within the coding sequence in the region that corresponds to the
second extracellular loop has been identified as the mutation region (Samson et al. 1996).
Hence, the development of new drugs is directed towards the inhibition of the co-receptor
CCR5. For example, Maraviroc, has been approved for human use in 2007 by the FDA
as well as other CCR5 antagonists that bind a hydrophobic pocket in the trans-membrane
domain of the CCR5. These antagonists bind not at the region in which V3-gp120
interacts with the co-receptor, but likely in a way that induces allosteric modification of
the second extracellular loop and consequently prevents the cellular fusion (Baba et al.
1999). Interestingly, the chemokine receptor CCR-5 interacts with some natural native
secreted proteins such as macrophage-inflammatory-protein (MIP)-1α, MIP-1β and
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RANTES to block the HIV-1 infection. However, nonpeptide CCR5 antagonists have
been also discovered. Thus, there is a need to develop other CCR5 antagonists for
inhibition of the CCR5 interaction (Wilen et al. 2012).
Cell fusion inhibitors are directed to bind the viral envelope glycoprotein gp41
and prevent the formation of the fusion pore. For example, Enfuvirtide, a 36 amino acid
peptide, binds directly to the HR-N region and prevents the formation of the hair pin
structure that enhances the formation of the fusion pore. (Moyle et al. 2003). However,
this drug has demonstrated to be ineffective against some strains that present mutation in
the HR-N region of the virus (Wiley et al. 2012). Another set of drugs that inhibit the
functionality of the glycoprotein, gp41, are D-peptides. These D-peptides target the
hydrophobic pocket of the gp41 as Enfuvirtide prevents the formation of the hair pin
structure of gp41 (Welch et al.2007).
RANTES Expression, regulation, and HIV entry inhibition
Regulated-on-Activation-Normal-T-cells-Expressed-and-Secreted (RANTES) is a
pro inflammatory human native protein that belongs to the chemokine family proteins
and has high affinity to CCR5 receptors in T cells. RANTES is expressed in cytotoxic
CD8+ phenotype and the helper CD4+ T cells as a response to inflammatory viral
infection (Song et al. 2000). Once cells have been activated by antigen binding, RANTES
mRNA is induced after three to five days of activation. This late expression is
characterized by a change in the expression patterns of T cells needed for T lymphocytes
cells to a mature. The human RANTES gene has been located on chromosome 17 and
composed of three exons and two introns (Figure 1.7) (Nelson, et al 1993). In addition,
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the RANTES Factor of Late Activated T Lymphocytes-1 (RFLAT-1) works as an
activator in the RANTES promoter cis-acting binding and regulates its expression. The
RFLAT-1 belongs to the family of zinc finger transcription factors (Song et al. 1999).

Figure 1.7: Human RANTES introns and exons
RANTES is a member of the CC chemokine family that forms a stable dimer at
neutral pH and has the tendency to aggregate at pH 4.0. Each monomer contains a Cterminal α-helix packed against a three-stranded antiparallel β-sheet and two short Nterminals β-strand (Figure 1.8). The N-terminal regions are considered important to dimer
formation (Skelton et al. 1995). RANTES has four cysteine residues contained in a 68
amino acids polypeptide. Two adjacent cysteine residues form the characteristic CC
sequence of chemokine family members (Figure 1.9) (Nishiyama et al. 2002).

Figure 1.8: dimer structure of RANTES

Figure 1.9: Amino acid sequence of human RANTES

12

RANTES function in the recruitment of T cells to the inflamed tissue and is a
powerful chemoattractant for many other cells as monocytes, NK cells, memory T cells,
eosinophils, and dendritic cells (Crawford et al, 2011). The high affinity between CCR5
receptor and RANTES make inhibition of the infection by HIV-1. RANTES, MIP-1α and
MIP-1β, are considered a suppressive factors during HIV-1 infection (Cocchi et al 1995).
It is known that aggregation of RANTES is important for chemotaxis activity even
though the physiological dimeric structure of RANTES has not been well defined (Appay
et al. 2000). RANTES possesses two distinct regions that have been identified as the
regions that interact with the chemokine receptor, CCR5. The N-terminal and the N-loop
region are the regions that have demonstrated interaction with the HIV’s co-receptor,
CCR5 (Nardese et al. 2001). The N-loop residues Phe 12, Ile 15, and Tyr 27 – Tyr 29,
(Figure 1.10) have been identified as contributors to the formation of large hydrophobic,
solvent exposed patches that provide a high docking interaction with the trans-membrane
protein, CCR5 (Nardese et al, 2001).

Figure 1.10: Dimeric structure of RANTES and critical amino acids residues
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RANTES chemokine analogues
New HIV-1 preventive and protective drugs used as microbicides are being
developed on mucosal surfaces to decrease the sexual transmission of the HIV. In that
context, RANTES is a natural inhibitor to prevent and block the entry mechanism of the
tropic HIV-1. Even though there is not universal agreement about the entry mechanism in
mucosal surface, the HIV-1 co-receptor CCR5 is known to be involved in the entry
process. Thus, the focus of research and development has been directed to the discovery
of effective microbicides that possess analogous function as the native RANTES
(Lederman et al, 2004).
Aminooxypentane (AOP)-RANTES is one of the first analogue antagonists of
CCR5 developed to protect macrophage and lymphocytes from infection. AOP-RANTES
was generated by the addition of an aldehyde-like group at the amino terminus of native
RANTES and then reacting with aminooxypentane. This peptide offers strong inhibition
of the co-receptor CCR5 and does not induce chemotaxis (Simmons et al, 1997).
Another

RANTES

analog,

Nα-(n-nonanoyl)-des-Ser1-[L-thioproline2,L-α-

cyclohexyl-glycine3]RANTES (PSC-RANTES) introduce a nonanoyl group, thioproline
and cyclohexylglycine in the position that correspond to the first three amino acids
(Ser,Pro,Tyr) of the native RANTES. Initially tested in rhesus macaques, PSC-RANTES
has resulted in the depletion of free CCR5 co-receptors (Lederman et al, 2004) This
discovery has led to the likelihood that PSC-RANTES involves long-term intracellular
sequestration of CCR5 and also a strong CCR5 signaling activity (Hubert et al, 2008).
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Further investigation of the PSC-RANTES has demonstrated to be fifty times more
potent than AOP-RANTES (Hartley et al, 2004).
PSC-RANTES is a potentially microbicide that raise the potential for a more
affordable and environmentally stable compounds. Although, PSC-RANTES has
demonstrated both high signaling activity and co-receptor sequestration, it has the
tendency to produce inflammation which enhances the chance for HIV-infection. Two
analogs called 5P12-RANTES and 6P4-RANTES have been identified using PSCRANTES as the platform molecule (Hubert et al, 2008). 5P12-RANTES features high
anti-HIV activity but no CCR5 signaling and no CCR5 sequestration. However, 6P4RANTES offers high anti-HIV activity, high CCR5 signaling activity and high CCR5
sequestration. Both analogues offer high resistance to hydrolysis at temperature in the
range of 40 to 55°C. In addition, both are very stable at acidic vaginal pH (4.0) and have
resistance to degradation during incubation with human cervicovaginal lavage and human
semen (Cerini et al, 2008). However, the principal characteristic of both analogues is the
primary structure that contains naturally occurring amino acids. This makes them suitable
for large scale recombinant production by using microorganism such as yeast (Hubert et
al, 2008).
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CHAPTER II
CELL LINE CONSTRUCTION AND FERMENTATION DEVELOPMENT
Abstract
Pichia pastoris is a well know microorganism that has the ability to express extra
and intracellular recombinant proteins. Pichia pastoris has a large amount of genotype
strains that are derived from the wild-type strain Y-11430. The X-33 is also a wild-type
strain that have the capability to accept recombinant gene. A great variety of expression
vectors for P. pastoris enables the facile development of multiple clonal linages
containing the recombinant gene. Using a yeast shuttle vector one can select clones that
can express the protein of interest from those who are not capable of expression. The
presence of the alcohol oxidase enzyme (AOX) in the genomic information of the yeast
Pichia pastoris is particularly beneficial for selection and induction of cells that produce
the protein of interest. The AOX enzyme allows the usage of methanol as the sole carbon
source for the production of biomass and energy metabolism. The expression of protein
and posterior translocation depends in the particular features of some shuttle vectors. For
example, the pPICZαA vector has the ability to secrete the protein of interest out of the
cell into the fermentation broth. Secretion is achieved by the addition of the α-leading
factor transcriptional unit. The leading factor is removed in the Golgi apparatus by
enzymatic action of the KEX2 protease that allows the secretion of the protein of interest.
In this research, The X-33 wild type is used as host microorganism for the vector
pPICZαA–5P12-Rantes.
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The fermentation development focused in both the determination of the maximum
growth rate and the establishment of a relation between the methanol growth rate and the
methanol feed rate. The rate of growth was determined to be 0.0807 h-1 using methanol as
sole carbon source. The equation νMeOH = 0.7573 (µMeOH) + 0.0024 relates the methanol
feed rate with the methanol growth rate.
Introduction
Pichia pastoris as a suitable system for heterologous protein expression
Pichia pastoris, recently reassigned to its genus Komagataella pastoris (P.
pastoris) (Kurtzman et al, 2009), has been largely used for recombinant protein
production. (Cregg et al, 2009). The P. pastoris system has the potential to express
correctly folded proteins, grow at large cell density, use methanol as sole carbon source,
and produce large amounts of protein using the alcohol oxidase (AOX) promoter that
drives the gene expression of the desired protein (Daly et al, 2005).
The formation of haploids during P. pastoris life cycle offers advantages for the
isolation and phenotype characterization of mutants. Mating occurs on nitrogen
limitations and diploid cells are formed. P. pastoris is by definition homothallic and after
mating the resulting diploid products can be maintained in the state by shifting to a
standard growth medium.

In this context, P. pastoris life cycle enables genetic

manipulation due to its stability in the haploid state (Cregg et al, 1998).
P. pastoris offer a great variety of strains that can facilitate and enhance the
production of recombinant proteins. For example, the wild type strain, X-33, is a positive
methanol utilization strain. The strain GS115 is defective in the histidine dehydrogenase
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gene (his4), and its use allows transformants to be selected based on the ability to grow in
non-histidine containing media. The strain KM71 is a strain which chromosomal Alcohol
Oxidase 1 (AOX1) has been deleted. KM71 uses a weaker promoter alcohol oxidase 2
(AOX2) that metabolize methanol in a lower rate than AOX1. Some other strains have a
lower grade of vacuolar proteases that can degrade protein especially during high density
cell fermentation. SMD1165 and SMD1163 are defective in vacuolar proteases and may
help to reduce protein degradation (Higgins et al, 1998. Daly et al, 2005).
Expression vectors for P. pastoris have both common and specialized features.
All vectors contain an expression cassette which is composed of a promoter sequence
(commonly AOX1 promoter), multiple cloning sites for gene insertion and a
transcriptional termination sequence that allows efficient polyadenylation (Li et al,2007).
However, the most important feature is that all E. coli / P. pastoris shuttle vectors contain
an origin of replication for plasmid maintenance. These vectors also have functional
markers that make them usable for marker selection in both organisms (Cereghino et al,
2007). Specialized vectors are selected according to the expression requirements. For
example, there are vectors that favor intracellular expression, some that favor
extracellular secretion, some that offer different selectable markers or antibiotic
resistance, and some that use promoters other than AOX1 (Higgins, Busser et al, 1998,
Cereghino et al 2007). In this context, the vector pPICZαA induces extracellular protein
secretion using the alpha mating factor (α-MF) secretion signal. This vector uses zeocin
as antibiotic marker and allows plasmid integration to the AOX1 locus. These
characteristics make this vector an optimal option when extracellular expression is
required (Siren et al, 2006).
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The glyceraldehyde 3-phosphate dehydrogenase (GAP) and AOX1 promoter are
the more useful promoters during heterologous protein expression. The GAP promoter
allows strong constitutive expression using either glucose or glycerol. However, the GAP
promoter activity in cells grown in glycerol is two-thirds of the level observed for glucose
(Cereghino et al, 2000). However, GAP promoter induce the production of acetate and
ethanol than may be harmful to the protein of interest (Li et al, 2007).
The AOX1 promoter is used to drive the expression of recombinant proteins to
high levels using methanol as sole carbon source (Daly et al, 2005). When AOX1 enzyme
represents the 30% of the total protein content, AOX1 production may be induced by
switching carbon source from glycerol to methanol. However, the importance of using
AOX1 as a drive promoter resides in its functionality to metabolize large amounts of
methanol to produce for both production of cell material and metabolism (Bollok et al,
2009).
Alcohol Oxidase (AOX) is the first enzyme that acts on the metabolic pathway of
methanol. AOX is an oligomericflavoprotein that contains the flavin adenine dinucleotide
(FAD) and the modified flavin adenine dinucleotide (mFAD). These flavoproteins are
non-covalently attached to AOX to accomplish electron transfer (Bystrykh et al, 1991.
Daly et al, 2005). P. pastoris has two genes that code for the alcohol oxidase enzyme:
alcohol oxidase 1 (AOX1) and the alcohol oxidase 2 (AOX2). The AOX1 is responsible
for at least 90% of the AOX activity, and AOX2 accounts for the rest (Pla et al, 2006).
AOX is sequestered within the peroxisome along with catalase. AOX oxidizes methanol
to formaldehyde and hydrogen peroxide that it is degraded by catalase (Figure 2.1). A
portion of the produced formaldehyde leaves the peroxisome and is further oxidized to
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formate and carbon dioxide by cytoplasmic dehydrogenases. These last reactions are the
source of energy for cells growing on methanol. (Cereghino et al, 2000)

Figure 2.1. The methanol pathway in P. pastoris. 1 alcohol oxidase; 2 catalase; 3
formaldehyde dehydrogenase; 4 formate dehydrogenase; 5 dihydroxyacetone synthase; 6
dihydroxyacetone kinase; 7 fructose 1,6-biophosphate aldolase; 8 fructose 1,6biphosphatase.
P. pastoris phenotypes are selected on the capacity to metabolize methanol:
methanol utilization positive (Mut+), Methanol utilization slow (Muts) and Methanol
utilization negative (Mut-). These phenotypes are the possible outcomes that can result
after homologous recombination in the AOX1 promoter (Daly et al, 2005).
Transformants with Mut+ can synthesize large amounts of methanol due to the expression
of AOX1. Muts transformants can processes low quantities of methanol mainly caused by
the deletion of the AOX1 and expression of the weaker enzyme AOX2. Mut- phenotypes
contain neither AOX1 nor AOX2 in its genome (Pla et al, 2006).
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P. pastoris allows high levels of recombinant protein expression due to its ability
to reproduce and maintain high-cell densities during fermentation (Inan, et al 1999).
Fermentation process can be subdivided in four operative sections. First, the batch phase
in which P. pastoris grows freely using a salt medium with a non-fermentable carbon
source like glycerol. Second, the fed-batch phase is mainly characterized for the growth
under glycerol grow-limiting rate. Under this phase sub-products produced during batch
phase like ethanol are used by the yeast, making them ready for the use of methanol
(Zhang et al, 2000). Third, the transition phase characterized for a first injection of
methanol and a constant reduction of the glycerol feed rate for three hours. This phase is
of particular interesting because it defines the time zero for induction (Zhang, et al 2000).
Finally, the methanol induction phase in which the carbon source is fed at growth
limiting rate to avoid any prejudicial accumulation that may affect the cell. The induction
phase activates the expression of the protein of interest (Cereghino et al, 2000).
Material and Methods
DNA Sequence construction, transformation and multiple inserts screening
5P12-Rantes DNA sequence was obtained from The Mintaka Medical Research
Foundation trough the Biological Process Development Facility (BPDF) at University of
Nebraska – Lincoln (UNL). The DNA sequence was synthesized by Gene Script and
inserted in the pUC57 vector. The pUC57 containing the 5P12-Rantes gene was
subcloned into E. coli DH5α strain. The E. coli DH5α–pUC57–5P12-Rantes strain was
plated in Lb agar plate containing 100 mg/L ampicillin. Then, the pUC57–5P12-Rantes
vector was extracted and purified as instructed in the DNA qiagen Miniprep kit. The
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purified vector was digested with restriction enzymes Not I and Xho I. The digested
solution is separated using agar gel. The DNA sequence that corresponds to the 5P12Rantes was extracted from the gel and then purified. The purified 5P12-Rantes sequence
is inserted into a previously digested pPICZαA vector and sub cloned into E. coli DH10B
strain. Purified DNA sequence was shipped for sequence confirmation. Finally, the E.
coli DH10B strain containing the pPICZαA–5P12-Rantes sequence was plated in Lb
agarose gel with 5µg/L zeocin. 10 mL Lb broth is inoculated with 1µg of a well round
shape form colony. The Lb broth is incubated at 37°C and 200 rpm for 10 hours. 1.5 ml
of the resulting broth was treated as indicated in the Qiagen Miniprep Kit and later
digested with PmeI enzyme for DNA linearization.
P. pastoris wild type X-33 is used as the hosting microorganism. Fresh competent
cells are used for electroporation (Wu, et al 2004). Finally, P. pastoris transformation is
completed by electroporation as indicated in section of transformation in the Pichia
pastoris protocols (1998). The solution containing the transformants is plated in YSDS
agar plates containing 100, 200, 500, 1000 and 1500 µg/mL zeocin. Colonies started to
appear after 3 days of incubation at 30°C.
Table 2.1: X-33 amplification in YSDS/zeocin agar plates
YSDS/ Zeocin concentration

Colonies

100 µg/mL

25

200 µg/mL

16

500 µg/mL

6

1000 µg/mL

2

1500 µg/mL

0
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Mut+ phenotype selection
Phenotype selection of the transformants is performed to discriminate strains with
AOX activity from those whose AOX sequence has been deleted. A number is assigned
to the each colony that grows in the YSDS plates. Each colony is transferred from the
YSDS plate to Minimal Dextrose (MD) agar plate and the same colony is used to
inoculate Minimal Methanol (MM) agar plates. Plates were incubated at 30°C and
checked for colony formation every 24 hours. 3 colonies grew after 35 hours of
inoculation. The colonies with the assigned number 8, 30 and 32 were chosen for further
processing. This selection was based in the high zeocin resistance assuming that higher
resistance is an indication of multiple sequence insert. The selected clones are assumed to
have a better capability to metabolize methanol. All colonies grew after 48 hours of
incubation however this indicates a slow tendency to metabolize methanol.
Table 2.2: Clones with high zeocin resistance
Colony Number

Zeocin Resistance

8

500 µg/mL

30

200 µg/mL

32

200 µg/mL

Selection of the clone is completed by running 3 fermentation batches using Basal
Salts Medium (BSM). Each batch ran at 1g/L methanol saturation in which clone number
8 showed to have a better capability to metabolize methanol as carbon source. Even
though, clones number 30 and 32 have zeocin resistance both have demonstrated
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methanol accumulation during fermentation reaching about 700 and 1300 ppm of
methanol accumulated in the vessel during induction phase.
Fermentation Development
Fermentations were developed using 3 5-liter Bioflo III fermentor interfaced with
the computer base software AFS – Biocommand32 (New Brunswick Scientific Co.
Edison, GA). The outlet gas was diverted into two lines. The first line was directed to
monitor the methanol concentration in the fermentation broth using a MC-168 methanol
concentration monitor and controller (PTI instruments, Inc., Kathleen, GA). The second
line was derived to a process mass spectrometer for on-line fermentation gas analysis
(PrimaδB VGgas Thermo-Fisher Scientific) The AFS-Biocommand32 interface was used
to monitor and control a peristaltic pump used for methanol feed (Model 101U/R,
Watson-Marlon Ltd. England), scale (Model PG 12001-S, Mettler Todelo, Switzerland),
and the methanol concentration monitor and control.
The main objective of the fermentation development process, using P. pastoris as
host, is to obtain a high protein production level with a low methanol accumulation and
high cell density. Fermentation process may be subdivided in four sections: Batch phase,
glycerol fed batch phase, transition phase and induction phase.
The fermentors were inoculated with 100 ml of BMGY incubated for about 19
hours with 1 mL of stock culture at 30°C and 250 rpm shaking rate. Once the optical
density at 600 nm (OD600) reached a value between 8 and 10 the shake flask was stopped
and aseptically 100 mL was transferred to each fermentor.
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Each fermentation batch used 2L of BSM. Before inoculation, 8.7 ml of PTM1
salts and 2 mL of 5%v/v antifoam were injected directly to the vessel. The fermentation
medium pH was adjusted to 5 with 20–30% ammonium hydroxide. The temperature was
set up to 30°C and dissolved oxygen to 40%. Agitation was initially at 400 revolutions
per minute (rpm) and set up in cascade response so the agitation will increase to maintain
dissolved oxygen (DO) at 40%. These conditions are maintained until all the initial
glycerol contained in BSM is consumed.
The fermentation batch phase has the objective to generate biomass prior to the
production of protein. Glycerol, included in BSM, is used as the sole carbon source in the
phase and the microorganism grows at non-limiting carbon supply. The table 2.3 provides
information about the data extracted from this phase. Since the glycerol concentration in
BMS is the same for all runs the results showed have little variability.
Table 2.3: Data from fermentation batch phase for a total of 20 experiments
Variable
Batch phase specific growth rate
Cell mass produced
Glycerol yield

Range
0.1766 - 0.1769 h-1
98 – 100 g wet cells/L
2.45 – 2.5 g wet cells/g glycerol

The depletion of glycerol in BSM is characterized by a rapid increment in the DO
value that is also known as DO spike which indicates the culmination of the batch phase
(Inan et al 1999). During the glycerol fed-batch phase, a solution of 63% weight/volume
(w/v) glycerol with 12 mL/L PTM1 salts is fed to the fermentation broth at 20
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gr/Liter/hour feed rate (Zhang, 2000). During this phase all the sub-products (ethanol,
acetate) produced in the batch phase are used for cell maintenance and growth (Zhang, et
al2000). Glycerol fed-batch phase is completed after 1 hour of glycerol fed to obtain
about 120 to 125 g wet cell/L.
Transition phase starts after 1 hour of glycerol feed. 1 g MeOH/L (1.26 mL/L)
broth is injected into the fermentor and marks the time zero for induction. The glycerol
feed rate is decreased from 20 g/L/h to 0 g/L/h over 3 hours. The mass spectrometer
shows an increase in the methanol concentration in the fermentor after the first injection.
The concentration of methanol decreases over time indicating the capability of cells to
metabolize methanol. The transition phase is particularly important due to the gentle
switch from glycerol to methanol will improve the cell ability to metabolize methanol
(Zhang, et al 2000).
Methanol fed-batch phase starts once the methanol concentration measured by the
mass spectrometer has decreased about 50 ppm. Methanol feed profile is developed to
estimate both maximum growth rate and optimal process conditions.
Maximum growth rate development
The maximum growth rate indicates the rate at which P. pastoris grows in a nonlimiting carbon source environment. To obtain the maximum growth rate (µmax), a
fermentor was set up with 2L of BSM with 8.7 mL of PTM1 salts at pH 5.0. After DO
spike, glycerol is fed at 40 g/h over 1 hour. 1 g MeOH/L was injected in the fermentor
and the concentration was determined by the methanol sensor. The processed outcome
was monitored with the AFS-Biocommand32 interface. 1g MeOH/L saturation is
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indicated by a constant value in the Biocommand trend view. Once the methanol
concentration decrease, a second injection is performed and methanol feed starts once the
constant saturation value is reached. Methanol pump feed rate is controlled by the AFSBiocommand32 interface to maintain 1g MeOH/L saturation value in the fermentor. The
table 2.4 shows the values to determine the specific growth rate.
Table 2.4: Fermentation values for maximum growth rate determination
Induction time

Wet Cell Weight

Fermentor Volume

Biomass

5.60

135.4

2.05

277.57

11.01

190.2

2.23

424.146

12.98

215.3

2.32

449.496

14.00

232.3

2.37

550.551

Maximum Growth Rate
600

Biomass

500

y = 175.98e0.0807x
R² = 0.9991

400
300
200
100
0
0.00

5.00

10.00

15.00

Induction Time
Figure 2.2 : Exponential regression to calculate maximum growth rate

The exponential regression shows that the specific growth rate has a value of 0.0807 h-1.
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Methanol Feed profile development
Methanol feed profile is developed to obtain an equation that will determine the
relationship between the methanol consumption rate (νMeOH) and the growth rate during
the methanol fed-batch phase (µMeOH). The growth rate will be limited by the amount of
methanol fed during the methanol fed-batch phase. Four runs at different growth rates are
performed. An equation proposed for methanol consumption rate (Sinha et al, 2003) is
used as reference to determine the real relationship for this specific clone.
Table 2.5: Values for methanol consumption rate determination.
Fermentation

Proposed µ*MeOH

Real µMeOH

Real νMeOH

1

0.01

0.009

0.0099

2

0.025

0.0259

0.0225

3

0.04

0.0399

0.0302

4

0.06

0.0645

0.0524

The relationship between µMeOH and νMeOH is determined by linear regression with
the calculated values (Zhang, et al 2000). The final equation is:
νMeOH = 0.7573 (µMeOH) + 0.0024 (eq. 2.1)
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Results and Discussion
The development of P. pastoris growth rate and methanol consumption rate is
important to the precise control of the amount of methanol fed during the methanol fedbatch phase. This information will allow to manage the methanol feed pump that
ultimately is controlled by the AFS-Biocomand32 interface in which this data is entered.
Determination of the maximum growth rate for this specific clone is useful
information towards the development of the fermentation process. The calculated value
of 0.0807 h-1 was obtained at 1g/L methanol saturation in the fermentor vessel.
Concentration higher than 3.75 g/L methanol saturation will have inhibitory effects on
the specific growth rate (Zhang, et al 2000).
The equation proposed by Sihna et al 2000, was adjusted to the actual values that
correspond to this specific clone. For all four fermentations, methanol was fed in a quasisteady state condition at different exponential growth rates. This fermentation were
performed below the inhibitory growth levels (Sihna, et al 2000). The actual equation
(νMeOH = 0.7573 (µMeOH) + 0.0024) will be used in the experimental design for the
exponential growth and exponential methanol feed rate.
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CHAPTER III
RESPONSE SURFACE METHODOLOGY AND CENTRAL COMPOSITE
DESIGN
ABSTRACT
Fermentation process development focuses upon the optimization of expression of
a target molecule. The central composite design and the response surface methodology is
a mathematical and statistical tool for evaluating the responses necessary to optimize a
fermentation process (Dey et al 2001, Hao et al 2006). P. pastoris is frequently used for
the production of recombinant heterologous proteins (Inan, et al 1999). However, there
are many variables that may affect cell’s productivity. These variables may include pH,
temperature, Dissolve Oxygen, Agitation speed, medium composition, methanol growth
rate and methanol feed rate (Inan et al 1999). This research is focused in the evaluation of
the effect of temperature, pH and Methanol growth rate are evaluated in their effect on
the total protein secretion, active protein secreted and Specific yield in the yeast P.
pastoris.
The central composite design (CCD) is an experimental design used to allocate
the operation variables into a range of evaluation. Temperature, pH and methanol growth
rate are evaluated in a range defined by the CCD.
The response surface methodology (RSM) provides the statistical elements
necessary for the evaluation of Temperature, pH and methanol growth rate. The RSM
focused in the construction of geometrical models that can predict the behavior of the
factors in the area of evaluation. In addition, the RSM enables the independent evaluation
of each factor and their interaction within the proposed model.
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INTRODUCTION
Response surface methodology (RSM) is a collection of mathematical and
statistical methods to evaluate relationships between a group of quantitative independent
variables and one or more responses. The RSM enables to evaluate operation variables
that may or may not have significant effect in the main response (Myers 1976, Parampalli
et al 2007, Inan et al 1999). The optimization of fermentation process is an important step
in the development of feasible processes (Ghosalkar et al 2008). The fermentation
process optimization implies the evaluation of medium composition, glycerol feed rate,
methanol feed rate, temperature, pH, dissolve oxygen, air/oxygen flow rate and agitation
speed (Inan, et al 1999). In this study, temperature, pH and methanol growth rate are
evaluated to determine their effect in the total amount of 5P12-Rantes produced, the
active 5P12-Rantes and the specific yield.
The central composite design, CCD, is used to build a second order experimental
model (Myers, 1976). CCD is composed of a factorial design, a set of central points, and
axial points equidistant to the center point.
The factorial design component of CCD is of the class 2k factorial where k
represents the number of relevant factors or variables. Each of the variables is taken at
two levels meaning that each variable has a low and high numeric value. A coded
numeric value of -1 and +1 is assigned to represent the variable’s low and high values.
The geometric representation of a factorial is a cube in which each corner represents an
interaction of the factors. In this perspective, 8 interactions are to be evaluated when 3
processing variables are selected to determine their significance in the final response
(Myers, 1976).
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The axial component of CCD refers to the points that are equidistant from the
center of the cube formed for the factorial design. A spherical design is obtained in the
reason that there is an equal variance from the center to all the points in the sphere. In
consequence, there is a positive axial value (+α) and a negative axial value (-α). The axial
points add two more levels in each variable. The α value is calculated from the equation
α = (ni)1/4. Where, ni represent the number of interactions obtained from the
factorial design. Thus, for 8 interactions α = 1.682 (Myers, 1976).

The central point component in the CCD is the average of the high and low values

determined in the factorial design. The central point or zero point may be defined as the
region where the optimal conditions are supposedly met. The addition of the central point
in the design increases the level’s design in one unit to a total of 5 levels for each
variable.

Figure 3.1. Layout of the Central Composite Design (CDD) for 3 variables at 5 levels
The RMS allows the introduction of blocks that facilitate the accomplishment of
experiments. Blocking is justified based on the physical and time limitations to run
experiments. However, blocking may have some effects over the final response. If the
estimations of the independent and interaction effects of the selected variables are not
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affected by blocking, the inclusion of blocks in the experimental design is justified
(Myers, 1976).
The selection of variables for the analysis using RSM is completed in order to
determine which factor may or may not have an important effect in the final response.
Basic information about the protein sequence, pH stability, post transformational
modifications will provide a better understanding of possible factors that can affect the
protein production during fermentation.

GROWTH CONDITIONS
Methanol growth rate
The methanol growth rate is determined during the induction phase. The amount
of methanol fed during this phase is calculated using equation 2.1. The methanol feed rate
is established by values determined in the CCD. The methanol feed rate determines how
fast the microorganism grow using this carbon source. However, there is an important
link between the methanol feed rate and the amount of protein produced in the reactor
vessel during the induction phase (Zhang, et al 2000). A lower methanol feed rate implies
a slow growth rate and a slow protein production that could or could not be beneficial for
the overall production. In other hand, a high methanol feed rate results in a rapid grow of
the microorganism and an accelerated protein production that may be affected by the
elevated methanol feed rate. (Sinha, et al 2003). Nevertheless high cell density is reached
in the least amount of time and the accumulation of methanol in the fermentation vessel
could be detrimental for the microorganism. (Sihna, et al 2003, Zhang et al 2000).
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Temperature
Pichia pastoris generally uses temperature of 30°C (Wegner, US Patent 1983).
However, the cell productivity may be affected by the temperature at which protein
secretion is induced. Positive effects in production of heterologous recombinant protein
have been reported when lowering temperature (Dragosits, et al 2008). Proteins tend to
have more stability and proteases activity is decreased when fermentation is carry out at
low temperatures. Nevertheless, low temperature during induction phase decrease the
activity of the AOX enzyme and the tendency of accumulate methanol may have negative
effects in the protein production. Temperatures ranging from 24°C to 30°C during the
induction phase are preferably selected in order to evaluate their effect in the responses
(Inan, et al 1999).
pH
Pichia pastoris has the ability to grow in a broader range of pH values.
Expression of recombinant proteins were investigated in pH values from 3 to 7. The
protein stability and activity is the main response to evaluated at different pH values
(Inan et al 1999, Zhang et al 2000, Slininger et al 1990). The Acidity or alkalinity in
which the process is run has an effect in both microorganism growth rate and protein
production.
5P12-RANTES PROPERTIES
The 5P12-Rantes, an anti-HIV microbicide, has a molecular weight of 7.905 KDa
and isoelectric point of 10.2. This protein was developed with the final intention to be
used as a vaginal topical gel and prevent the spread of HIV infections disease. The acidic
environment of the vagina (3.5 to 4.2) dictates the 5P2-Rantes stability and activity under
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this condition (Gaertner, et al 2008). The amino acid sequence of 5P12-Rantes was
established after an exhaustive investigation in which the inclusion of a motif Q-G-P-P at
the N-terminus (Figure 3.2) reveals a remarkable anti-HIV activity over the other
candidates. The next five amino acids residues affect both anti HIV-potency and the
capacity for receptor interaction (Gaertner, et al 2008). The complete 5P12-Rantes amino
acid sequence has a total of 69 amino acid residues distributed as follow: Q G P P L M A
TQSCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKN
RQVCANPEKKWVREYINSLEMS

Figure 3.2: 5P12-Rantes sequence at the N terminal

The stability and activity of the 5P12-Rantes is limited by the spontaneous
formation of a Pyro-glutamic residue at the N-terminal of the amino acid sequence and
the formation of two disulfides bonds between the cysteine residues. The formation of the
pyroglutamic acid (pyro-Q) enhances the protein stability, hydrophobicity and anti HIVpotency. In addition, the pyro-Q improves low intracellular sequestration and decrease
the G protein-linked signaling activity (Gaertner, et al 2008). The N-terminal glutamine
(Q) is converted into pyro-glutamic acid (pyro-Q) (Figure 3.3) (Dick, et al 2006). The
two disulfide bonds occur between the cysteine residues at position 11 with 35 and 12
with 51 to form a G shape structure. The human Rantes structure has an analogous shape
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to the 5P12-Rantes (Figure 3.4) (Burke-Gaffney et al 2002). The pyro-Q formation is an
important post translational modification with effects in the functionality of the protein
5P12-Rantes. The formation of pyro-Q at the N-terminal protects the protein against
proteolitic degradation (Kumar et al 2012).

Figure 3.3: The conversion of glutamine to pyro-glutamic acid

The 5P12-Rantes stability and activity delimit the pH and temperature ranges of
operation. However, the formation of the pyro-Q at the N-terminal during fermentation
has not been investigated (Dick, et al 2006). Pyro-Q formation is induced by the increase
of temperature in a non-enzymatic reaction. (Kumar et al, 2012)

Figure 3.4: Human Rantes G shape with 2 disulfide bonds. The chemotaxis effect
depends of the formation of the G-shape.
Transformation of the un-cyclized form to cyclized is achieved by heating up
purified 512-Rantes solution at 60°C, pH 6.0 and 100mM potassium phosphate. Even
though this purification step maximizes the conversion of un-cyclized 5P12-Rantes, the
usage of chemicals and energy increase the cost of downstream processing.
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MATERIAL AND METHODS
Central composite design
A second order design composed of 3 blocks. 3 factors at 5 levels CCD was used
to investigate the effect of methanol growth rate, temperature and pH in the production of
5P12-Rantes, 5P12-Rantes activity and specific yield. The CCD comprises a total of 20
experiments: a full factorial design (8 experiments), 6 axial points, and 6 central points. 3
blocks were used to subdivide the experiments in three groups. 4 factorial points with 2
central points for the first two blocks and the third one comprise 6 axial points with 2
central points. Each block represents a bioreactor and 2 central points are proposed to
estimate the error for each bioreactor.

Table 3.1: 3 factors at 5 levels estimated values
Factor

Axial (-α)

Low (-1)

Normal (0)

High (+1)

Axial (+α)

Methanol growth rate (MeOHGR) h-1

0.010

0.016

0.025

0.0339

0.040

Temperature (T) °C

24.06

25.25

27.00

28.75

29.94

pH

1.98

2.50

3.25

4.00

4.51
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Table 3.2: CCD matrix for 3 factor 5 level 3 blocks
Coded Values

Block

Un coded values

Lot Number

MeOH (X1)

Temp (X2)

pH (X3)

MeOH

Temp

pH

1

-1

-1

-1

0.0161

25.25

2.50

MK-GR- 11

1

+1

+1

-1

0.0339

28.75

2.50

MK-GR- 05

1

+1

-1

+1

0.0339

25.25

4.00

MK-GR- 13

1

-1

+1

+1

0.0161

28.75

4.00

MK-GR- 08

1

0

0

0

0.0250

27.00

3.25

MK-GR- 16

1

0

0

0

0.0250

27.00

3.25

MK-GR-17

2

+1

-1

-1

0.0339

25.25

2.50

MK-GR-20

2

-1

+1

-1

0.0161

28.75

2.50

MK-GR-10

2

-1

-1

+1

0.0161

25.25

4.00

MK-GR- 07

2

+1

+1

+1

0.0339

28.75

4.00

MK-GR- 14

2

0

0

0

0.0250

27.00

3.25

MK-GR-18

2

0

0

0

0.0250

27.00

3.25

MK-GR-21

3

-1.682

0

0

0.0100

27.00

3.25

MK-GR-02

3

+1.682

0

0

0.0400

27.00

3.25

MK-GR-04

3

0

-1.682

0

0.0250

24.06

3.25

MK-GR-12

3

0

+1.682

0

0.0250

29.94

3.25

MK-GR-09

3

0

0

-1.682

0.0250

27.00

1.99

MK-GR-06

3

0

0

+1.682

0.0250

27.00

4.51

MK-GR-15

3

0

0

0

0.0250

27.00

3.25

MK-GR-22

3

0

0

0

0.0250

27.00

3.25

MK-GR-01
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Dry cell weight
Dry cell weight, DCW, is determined using a correlation between the data
obtained from the optical density at 600 nm (OD600) and the DCW in g/L. The optical
density is measured using a UV spectrometer cary 50. The Varian Cary 50 UV-VIS
spectrometer is set up at a wavelength of 600 nm. This equipment allows accurate
measurements when absorbance is determined between 0 and 1. In consequence,
dilutions are performed in the original sample once high cell concentration is reached in
the fermentor vessel. The dry cell weight (DCW) is calculated after washing the cell
resulting from the wet cell weight (WCW) calculations. Then the tubes are dried at 80°C
for 24 hours (Inan et al 1999, Kunert et al 2008). The final correlation between dry cell
weight and OD600 is indicated in the following equation.
DCW (g/L) = 0.2547 (OD600) + 0.1902 (Eq. 3.1)
The calculated DCW represents around 20% of the WCW for a total of 20
experiments. The DCW estimated values are to be used in the determination of the
specific yield in the final response.

DCW vs OD-600

120

y = 0.2547x + 0.1902
R² = 0.9913

DCW g/L

100
80
60
40
20
0
0

100

200

300

400

500

OD - 600

Figure 3.5: Linear regression to estimate relationship between DCW and OD600.
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5P12-Rantes protein essay
5P12-Rantes is analyzed at 280 nm of absorbance using high performance liquid
chromatography (HPLC-Waters). A strong cation-exchange (SCX) column is used to
perform the analysis (PolySulfoEthyl ATM, 100x4.6mm, 5 µm, 300Å, PolyLC Inc.
104SE0503). The buffer solutions for this analysis are Mobile phase A: 50nM 2-(Nmorpholino)ethanesulfonic acid (MES) at pH 6.4, Mobile phase B: 50nM MES and 1M
Sodium Chloride (NaCl) at pH 6.4, Mobile phase C: 0.45 µm filtered water and Mobile
phase 40mM Ethylenediaminetetraacetic acid (EDTA).
The HPLC passivation procedure is achieved by rinsing the installed column with
mobile phase C and then mobile phase D at 0.1mL/min and 1.0 mL/m respectively. After
passivation the column is rinsed with mobile phase B at 0.5ml/L and then mobile phase A
at 1.0 mL/min.
The SCX column is heated up to 40°C and then each sample is loaded in the
system. The table 3.3 shows the gradient used in the HPLC system.
Table 3.3: HPLC mobile phase gradient
Step

Time (minutes)

Flow (mL/m)

%A

%B

1

0

1.0

100.0

0.0

2

2.0

1.0

100.0

0.0

3

8.0

1.0

70.0

30.0

4

40.0

1.0

45.0

55.0

5

43.0

1.0

0

100.0

6

45.0

1.0

100.0

0.0

7

50.0

1.0

100.0

0.0
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5P12-Rantes is eluted in the 16 and 19 minute range (Figure 3.6). Two different
retention time reflex the existence of two forms of the protein. The 5P12-Rantes with
pyroglutamic acid (cyclized form) at the N-terminal is eluted at 16 minutes. Meanwhile,
the form with glutamine (un-cyclized form) at the N-terminal is eluted at 19 minutes. The
total concentration of 5P12-Rantes is a result of the sum of the peak area of both cyclized
and un-cyclized form.

Figure 3.6: Chromatogram for quantitative analysis of 5P12-RANTES at different
times during the methanol fed-bath phase
Specific Yield
The Specific yield represents the ratio of the total amount of 5P12-Rantes
produced by each batch and the dry cell weight at the end of fermentation. The specific
yield provides the experimenter information about the efficiency of the cell in producing
both cyclized and un-cyclized 5P12-Rantes.
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Results and Discussion
Table 3.4 shows the results of the responses: The total 5P12-Rantes, the active
form of 5P12-Rantes and the Specific yield. The first response represents the sum of the
active and inactive form of 5P12-Rantes produced during fermentation. The active form
of the protein represents the concentration of cyclized 5P12-RANTES in the fermentation
broth. The specific yield is another way to measure the efficiency of the overall process.
Table 3.5 shows the runs at which the production of 5P12-Rantes is maximized.
These values correspond to the runs performed at the zero point.
Table 3.6 shows the conditions at which the maximum concentration of active
5P12-Rantes is achieved. This result shows that temperature has a important effect over
the formation of pyro-glutamic acid.
Even though these results shows some predictability of the responses doesn’t
provide, by themselves, a model in which interpolation of the variables can be performed.
The models for prediction of responses are to be evaluated using the response surface
methodology and the central composite design. These statistical tools will provide
equations that can be adjusted to the quantitative analysis and determine their accuracy
and precision.
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Table 3.4: Analytical results using SCX column

Lot Number

Total 5P12Rantes mg/L

Active 5P12Rantes mg/L

MK-GR- 11

40.60

17.92

Specific Yield
mg Total 5P12-Rantes
/ g Dry cell
0.1185

MK-GR- 05

26.20

12.98

0.0860

MK-GR- 13

34.85

10.13

0.0881

MK-GR- 08

3.54

2.13

0.0102

MK-GR- 16

55.14

29.03

0.1570

MK-GR- 17

53.53

23.96

0.1542

MK-GR- 20

22.43

12.50

0.0654

MK-GR- 10

39.53

30.32

0.1104

MK-GR- 07

21.80

3.98

0.0685

MK-GR- 14

27.19

7.55

0.0668

MK-GR- 18

57.08

24.49

0.1621

MK-GR- 21

56.29

26.10

0.1524

MK-GR- 02

22.15

9.44

0.0796

MK-GR- 04

48.64

19.05

0.1286

MK-GR- 12

2.12

0.84

0.0062

MK-GR- 09

32.08

14.86

0.0989

MK-GR- 06

0.27

0.10

0.0110

MK-GR- 15

0.30

0.03

0.0008

MK-GR- 22

55.81

26.35

0.1496

MK-GR- 01

56.42

26.91

0.1735
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Table 3.5: Experiments with high 5P12-Rantes concentration
MeOH Temp pH
Block

5P12-Rantes
MeOH Temp

pH

Id Number

X1

X2

X3

(mg/L)

1

0

0

0

0.0250 27.00 3.25

MK-GR- 16

55.14

1

0

0

0

0.0250 27.00 3.25

MK-GR- 17

53.53

2

0

0

0

0.0250 27.00 3.25

MK-GR- 18

57.08

2

0

0

0

0.0250 27.00 3.25

MK-GR- 21

56.29

3

0

0

0

0.0250 27.00 3.25

MK-GR- 22

55.81

3

0

0

0

0.0250 27.00 3.25

MK-GR- 01

56.42

Table 3.6: Highest production of active 5P12-Rantes
MeOH

Temp

pH

X1

X2

X3

-1

+1

-1

Block

2

5P12-Rantes
MeOH

Temp

pH

Id Number
(mg/L)

0.0161

28.75

2.50

MK-GR-10

30.32
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CHAPTER IV

CALCULATIONS AND ANALISIS OF VARIANCE
ABSTRACT
The analysis of variance (ANOVA) is a statistical test used in the analysis of
experimental data. The CCD model describes the behavior of the production of 5P12Rantes. This model is evaluated using analysis of variance. The ANOVA provides
statistical tools to evaluate statistical hypotheses. In this context, the acceptance or
rejection of the null hypothesis dictates the level of significance of each factor. Then, the
alternative hypothesis is adopted if the null hypothesis is rejected (Walpole, 2007). The
F-test is used to estimate the effect of each variable in the final response and whether or
not the null hypothesis is rejected. The null hypothesis is rejected if the value of Fcalculated (F-calc) is higher than the F-critical (F-crit). The rejection of the null
hypothesis implies some level of significance of the factor in the final response. The Pvalue helps to discriminate between the factors that are significant from those which have
not effect over the response. For example, a P-value lower than 0.05 indicates
significance. The level of significance increases as the value approaches to zero. The Ftest and the P-value evaluation determine the level of significance of each factor over a
particular response. The acceptance or rejection of the proposed model will depend on the
statistical analysis of the responses.
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INTRODUCTION
The analysis of variance (ANOVA) is a statistical method used in the testing of
statistical hypotheses. The statistical hypotheses are composed of the null hypothesis and
the alternative hypothesis. The acceptance of rejection of the null hypothesis is based in
the determination of value or F-calc. the F-calc represent ratio of the media square value
of any factor and the residual error. The F-crit value is determined in the F-distribution
probability table using the degrees of freedom of both numerator and denominator
(Walpole, 2007). The calculation of P-value is used to evaluate the significance of each
selected variable in the experiments. The standard value of 5% is chosen as standard
value of significance for the evaluation of responses using ANOVA. The data obtained
from the analytical analysis of the fermentation broth is used to perform the ANOVA
using the software Minitab 16.
HYPOTHESES
The proposed equation to define the responses defines the effects of the selected variables
(MeOHGR, T, pH). To define the response equation, X1, X2 and X3 are assigned to
MeOHGR, T, and pH respectively.
YTotal5P12-Rantes = µβ + β1X1 + β2X2 + β3X3 + β11X112 + β22X222 + β33X332 + β12X1X2 +
β13X1X3 + β23X2X3

(Eq. 4.1)

YActive 5P12-Rantes = µγ + γ1X1 + γ 2X2 + γ 3X3 + γ 11X112 + γ 22X222 + γ 33X332 + γ 12X1X2 +
γ13X1X3 + γ 23X2X3

(Eq. 4.2)
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YSpecific Yield = µδ +δ1X1 + δ2X2 + δ3X3 + δ11X112 + δ22X222 + δ33X332 + δ12X1X2 + δ13X1X3 +
δ23X2X3

(Eq. 4.3)

The null hypothesis state that there is not quantifiable effect of MeOHGR, T and
pH in the overall responses 5P12-Ranres, Active 5P12-Rantes and Yield. If this
hypothesis is true then:
H0β : β1 = β11 = 0, β2 = β22 = 0, β3 = β33 = 0, β12 = β13 = β23 = 0
H0γ : γ1 = γ11 = 0, γ2 = γ22 = 0, γ3 = γ33 = 0, γ12 = γ13 = γ23 = 0
H0δ : δ1 = δ11 = 0, δ2 = δ22 = 0, δ3 = δ33 = 0, δ12 = δ13 = δ23 = 0
The alternative hypothesis postulated that at least one of the coefficients is
different to zero. Then:
H1β : At least one β ≠ 0
H1γ : At least one γ ≠ 0
H1δ : At least one δ ≠ 0
F-TEST
The F-test is a statistical test based on an F-distribution under the null hypothesis.
The values obtained from the F-test will indicate the rejection or no rejection of the null
hypothesis. F-calculated (F-calc) is determined from the ratio of the mean squares (MS)
of factor, blocks, linear, factor squares and factor interactions and the error mean square
(MSe). The F-critical (F-crit) is the value obtained from tables of critical values of Fdistribution using the degrees of freedom of both numerator (dfn) and denominator (dfd).
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The rejection or not rejection of the null variable is based in the comparison of the F-calc
and F-crit. If the value of F-calc is greater than F-crit the null hypothesis is rejected.
Otherwise it’s not rejected.
P-VALUE
The P-value represents the probability of obtaining a value that is at least as the
extreme as the calculated value if the null hypothesis is true. It has been assumed that 5%
probability, α-value, is appropriate to evaluate the P-value. If the P-value is lower than
the α value indicates the rejection of the null hypothesis.
METHODS
The RSM was analyzed using the software Minitab-16 (Minitab®). The analysis
provides the corresponding ANOVA table for each response. Each response was
evaluated under the null hypothesis. The ANOVA table provides the sum of squares (SS),
the mean square (MS), the F-calc and the P-value. This analysis includes the evaluation
for each independent factor, blocks, linear factors, quadratic factors, interaction and the
error. The F-crit is obtained from tables of critical values F-distribution. The level of
significance or α-value is 0.05. The data evaluated using ANOVA directs to the rejection
of acceptance of the null hypothesis.
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Table 4.1: ANOVA for the total amount of 5P12-Rantes with R-square = 89.01% and 3
factors
Source

DF

SS

MS

F-crit

F-calc

P-

Reject

value

H0β

Blocks

2

423.49

156.58

4.46

1.45

0.290

No

MeOH

1

181.26

181.26

5.32

1.68

0.231

No

Temp

1

54.06

54.06

5.32

0.50

0.499

No

pH

1

125.06

125.06

5.32

1.16

0.313

No

MeOHGR* MeOHGR

1

60.30

301.98

5.32

2.80

0.133

No

Temp*Temp

1

1270.54 1757.38 5.32

16.31

0.004

Yes

pH*pH

1

4157.59 4157.59 5.32

38.58

0.000

Yes

MeOHGR *Temp

1

29.80

29.80

5.32

0.28

0.613

No

MeOHGR *pH

1

581.41

581.41

5.32

5.39

0.049

Yes

Temp*pH

1

102.39

102.39

5.32

0.95

0.358

No

Residual error

8

862.19

107.77

Lack-of-Fit

5

860.40

172.08

9.01

287.73

0.000

Yes

Pure error

3

1.79

0.60

Total

19

7848.08
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Table 4.2: ANOVA for the Active 5P12-Rantes with R-square = 86.26% and three
factors
Source

DF

SS

MS

F-crit

F-calc

P-value

Reject H0γ

Blocks

2

106.26

39.893

4.46

1.12

0.373

No

MeOHGR

1

1.81

1.811

5.32

0.05

0.827

No

Temp

1

75.12

75.121

5.32

2.11

0.185

No

pH

1

183.39

183.389

5.32

5.14

0.053

No

MeOHGR*MeOHGR 1

42.49

120.273

5.32

3.37

0.104

No

Temp*Temp

1

276.46

382.052

5.32

10.72

0.011

Yes

pH*pH

1

899.41

899.408

5.32

25.23

0.001

Yes

MeOHGR *Temp

1

20.00

20.003

5.32

0.56

0.475

No

MeOHGR *pH

1

147.32

147.319

5.32

4.13

0.077

No

Temp*pH

1

37.45

37.455

5.32

1.05

0.335

No

Residual error

8

285.18

35.647

Lack-of-Fit

5

270.89

54.178

9.01

11.37

0.036

Yes

Pure error

3

14.29

4.763

Total

19

2074.90
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Table 4.3: ANOVA for the Specific Yield (Total 5P12-Rantes (mg)/dry cells (g)) with Rsquare = 88.07% and three factors
Source

DF

SS

MS

F-crit

F-calc

P-value Reject
H0δ

Blocks

2

0.00166

0.00083

4.46

0.93

0.434

No

MeOHGR

1

0.00051

0.00051

5.32

0.57

0.471

No

Temp

1

0.01404

0.01404

5.32

15.7

0.004

Yes

pH

1

0.00758

0.00758

5.32

8.48

0.020

Yes

MeOHGR*MeOHGR 1

0.00233

0.00233

5.32

2.61

0.145

No

Temp*Temp

1

0.01378

0.01378

5.32

15.41

0.004

Yes

pH*pH

1

0.03241

0.03241

5.32

36.25

0.000

Yes

MeOHGR*Temp

1

0.00054

0.00054

5.32

0.6

0.460

No

MeOHGR*pH

1

0.00295

0.00295

5.32

3.3

0.107

No

Temp*pH

1

0.00106

0.00106

5.32

1.19

0.308

No

Residual

8

0.00715

0.00089

Lack-of-Fit

5

0.00682

0.00136

9.01

12.15

0.033

Yes

Pure

3

0.00034

0.00011

Total

19
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RESULTS AND DISCUSSION
The tables 4.1, 4.2 and 4.3 show “lack of fit” of the model. The P-value is lower
than the 0.01 level for the total amount of 5P2-Rantes. In addition, the P-values for both
the active 5P12-Rantes and specific yield are at the 0.05 level of significance. The
elevated level of significance indicates that the proposed model doesn’t accurately predict
the responses. However, The result obtained from the significance analysis does not mean
that the experiments are not run properly or that the data obtained is incorrect. It is more
accurate to conclude that the responses are very complex that cannot be fit using a second
order design.
The evaluation of the each proposed model directs to conclude that temperature
and pH have a great significance in the responses. Conversely, The Methanol growth rate
(MeOHGR) does not have significant effect in the responses. In consequence, this factor is
excluded out of the model to decrease the significance in the lack of fit.
A new model with 2 factors at 5 levels each is proposed. Temperature and pH are
used to evaluate the responses. It is noticeable form tables 4.5 and 4.6 that the lack of fit
has decreased for the active 5P12-Rantes and for the specific yield responses. However,
table 4.4 shows that the lack of fit for the 5P12-Rantes remains significant.
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Table 4.4: ANOVA for 5P12-Rantes with R-square of 81.24% and two factors

Source

DF

SS

MS

F-crit

F-calc

P-value Reject
H0β

Blocks

1

16.12

16.12

6.61

0.07

0.799

No

Temp

1

1841.60

1841.60 6.61

8.25

0.035

Yes

pH

1

762.22

762.22

6.61

3.42

0.124

No

Temp*Temp

1

1769.20

1769.20 6.61

7.93

0.037

Yes

pH*pH

1

3779.43

3779.43 6.61

16.94

0.009

Yes

Temp*pH

1

71.49

71.49

6.61

0.32

0.596

No

Residual error

5

1115.64

223.13

Lack-of-Fit

3

1114.16

371.39

5.41

501.16

0.002

Yes

Pure error

2

1.48

0.74

4.46

Total

11

5947.83
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Contour plot for Total 5P12-Rantes
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Figure 4.1.: Contour plot for the total 5P12-Rantes
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Figure 4.2: Surface response for the total 5P12-Rantes
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Table 4.5: ANOVA for Active 5P12-Rantes with R-square of 85.88% and two factors

Source

DF

SS

MS

F-crit

F-calc

P-value Reject
H0β

Blocks

1

0.25

0.250

Temp

1

445.47

pH

1

Temp*Temp

6.61

0.01

0.939

No

445.466 6.61

11.62

0.019

Yes

121.40

121.400 6.61

3.17

0.135

No

1

449.38

449.381 6.61

11.72

0.019

Yes

pH*pH

1

911.28

911.283 6.61

23.77

0.005

Yes

Temp*pH

1

2.34

2.341

6.61

0.06

0.815

No

Residual error

5

191.71

38.343

Lack-of-Fit

3

178.85

59.617

5.41

9.27

0.099

No

Pure error

2

12.86

6.431

4.46

Total

11

1357.68
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Figure 4.3: Contour plot for the active 5P12-Rantes
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Figure 4.4 : response surface for the active 5P12-Rantes
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Table 4.6: ANOVA for Active 5P12-Rantes with R-square of 81.35% and two factors

Source

DF

SS

MS

F-crit

F-calc

P-value Reject
H0β

Blocks

1

0.000053

0.000053

6.61

0.03

0.87

No

Temp

1

0.014738

0.014738

6.61

8.25

0.035

Yes

pH

1

0.005794

0.005794

6.61

3.24

0.132

No

Temp*Temp

1

0.014135

0.014135

6.61

7.91

0.037

Yes

pH*pH

1

0.029859

0.029859

6.61

16.72

0.009

Yes

Temp*pH

1

0.000520

0.000520

6.61

0.29

0.613

No

Residual error

5

0.008930

0.001786

Lack-of-Fit

3

0.008638

0.002879

5.41

19.68

0.05

No

Pure error

2

0.000293

0.000146

4.46

Total

11

0.047876

69

Contour plot for Specific yield
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Figure 4.5: Contour plot for Specific yield
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Figure 4.6: Surface response for specific yield
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CHAPTER V
RESULTS AND DISCUSSION
The clonal linage used in this research express the un-cyclized form of 5P12Rantes. The formation of the active of 5P12-Rantes for is produced in the Golgi
compartment when the translated protein is detached from the secretory signal (α-mating
factor) by the KEX2 protease. The formation of the pyro-glutamic acid (pyro-Q) at the Nterminal of 5P12-Rantes during fermentation is not an enzymatic reaction. The pyro-Q is
catalyzed by temperature during fermentation (table 4.5). The cyclization reaction is not
reversible. 5P12-Rantes protein is stable at the active form. The formation of the two
disulfide bonds is enhanced by the P. pastoris protein disulfide isomerase.
The results obtained from the ANOVA for each response using a second order
model with 3 factors at 5 levels indicate “lack of fit” of the proposed models. As
indicated previously, this lack of fit of the models indicates the complexity of the system
in which the 5P12-Rantes expression is evaluated. The outcomes obtained from this
analysis enable the evaluation of the effects of Methanol growth rate (MeOHGR),
Temperature and pH. This evaluation demonstrates that MeOHGR is not a significant
factor in the final responses. Conversely, temperature and pH have an important effect
over the final responses.
In order to decrease the lack of fit of the proposed models; a strategy is applied by
decreasing the number of factors involved in the responses. Since MeOHGR has no effect
in the final response, this factor can be excluded out of the model. Thus, a new design is
constructed using temperature and pH.
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The final outcome using the second order design with 2 factors at 5 levels each
confirms the decrease in the lack of fit for both the Active 5P12-Rantes and specific yield
responses. However, the lack of fit for the total 5P12-Rantes is recurrent and reflexes the
complexity of the response against the proposed model.
It is noticeable that the R-square value for the 3 responses drops from 89.01% to
81.24% for the total 5P12-Rantes, from 86.26% to 85.88% for the Active 5P12-Rantes
and from 88.07% to 81.35% for the specific yield. This is due to the amount of factors
used to predict the behavior of the response.
The models proposed to explain and predict the expression of active 5P12-Rantes
and specific yield are:
YActive 5P12-Rantes = - 1755.88 + 117.229 X1 + 120.224 X2 – 2.124 X112 – 16.468 X222 0.584 X1X2
YSpecific Yield = - 10.3011 + 0.6743 X1 + 0.8306 X2 – 0.0119 X112 – 0.0943 X222 - 0.0087
X1X2
The optimal values for temperature and pH at which the maximum expression is
reached determined using Minitab 16:

Response

Temperature °C

pH

Maximum Outcome

Active 5P12-Rantes

27.14

3.16

26.52 g/L

Specific yield

27.14

3.16

0.161 mg 5P12-Rantes/g cell
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Nevertheless the effect of methanol is disregarded from the proposed model, it is
important to consider that a growth rate at or above 0.8 h-1 will exceed the maximum
capacity of the cell to metabolize methanol and methanol will have detrimental effect on
the cell growth as indicated by Zhang (2000).
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FUTURE STUDIES
1. Evaluate the contribution of dissolve oxygen in the responses.
2. Evaluate the action of the enzyme glutaminyl cyclase in the formation of pyroglutamic acid for the active for of 5P12-Rantes during fermentation.

